Allergan emerged as battleground stock in the second quarter.

Carl Icahn initiated a position in the Dublin-based pharmaceutical company, buying 3.4 million shares, according to a regulatory filing on Monday.

Meanwhile, Andreas Halvorsen’s Viking Global shed its stake in the company by more than half — paring its stake to 1.9 million shares, a filing shows.

Other Allergan buyers include David Tepper’s Appaloosa Management, which added nearly 1 million shares to its existing stake, and Seth Klarman’s Baupost Group, which added nearly 300,000 shares.

Barry Rosentein’s Jana Partners completely exited its position in the Botox-maker, selling 447,000 shares, a filing reveals.

Allergan shares, which gained 1.8 percent on Monday, to $254.05, is down 18.7 percent this year.